ArticleCancer medicine2023

Effect of proprotein convertase subtilisin/kexin type 9 inhibition on cancer events: A pooled, post hoc, competing risk analysis of alirocumab clinical trials.

Kusha A Mohammadi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.